Derek Naccari, MD
Internal Medicine · Metairie, LANPI 1871980128
Payments from drug & device makers
Across 413 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Lilly USA, LLC$717
- AstraZeneca$699
- Bayer$542
- Novo Nordisk$429
- Boehringer Ingelheim$416
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,83899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 100 | $1,349 |
| Lilly USA, LLC | 55 | $717 |
| AstraZeneca(2 entities) | 27 | $699 |
| Bayer | 33 | $542 |
| Novo Nordisk | 28 | $429 |
| Boehringer Ingelheim | 24 | $416 |
| Amgen | 25 | $406 |
| GSK | 19 | $349 |
| Exact Sciences | 12 | $244 |
| Merck | 12 | $195 |
| AbbVie(2 entities) | 8 | $190 |
| Johnson & Johnson | 10 | $161 |
| Abbott | 8 | $155 |
| Astellas Pharma US Inc | 4 | $132 |
| Dexcom, Inc. | 6 | $115 |
| Sumitomo Pharma America, Inc. | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Inari Medical, Inc. | 1 | $106 |
| Novartis | 5 | $87 |
| Supernus Pharmaceuticals, Inc. | 2 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$247
- AIRSUPRA$111
- BREZTRI$111
- FLOWTRIEVER CATHETER, S$106
- CT THROMBECTOMY SYSTEM KIT$106
How this compares
$6,923 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $140,269 |
| FarxigaDapagliflozin Propanediol | 98 | $105,171 |
| EliquisApixaban | 91 | $98,409 |
| OzempicSemaglutide | 84 | $95,873 |
| JardianceEmpagliflozin | 77 | $81,570 |
| JanuviaSitagliptin Phosphate | 67 | $45,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $30,932 |
| XareltoRivaroxaban | 29 | $24,496 |
| KerendiaFinerenone | 21 | $23,100 |
| TrulicityDulaglutide | 12 | $14,587 |
| MyrbetriqMirabegron | 19 | $13,912 |
| LinzessLinaclotide | 11 | $9,864 |
| LyricaPregabalin | 11 | $6,351 |
| Atorvastatin Calcium | 745 | $5,895 |
| Levothyroxine Sodium | 497 | $4,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $717 | $154,856134 claims |
| PfizerEliquis, Lyrica, Paxlovid | $1,349 | $106,189120 claims |
| AstraZenecaFarxiga | $699 | $105,17198 claims |
| Novo NordiskOzempic | $429 | $95,87384 claims |
| Boehringer IngelheimJardiance | $416 | $81,57077 claims |
| MerckJanuvia | $195 | $45,26167 claims |
| GSKTrelegy Ellipta | $349 | $30,93249 claims |
| Johnson & JohnsonXarelto | $161 | $24,49629 claims |
| BayerKerendia | $542 | $23,10021 claims |
| Astellas Pharma US IncMyrbetriq | $132 | $13,91219 claims |
| AbbVieLinzess, Synthroid | $190 | $10,96733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Metairie
- Robert JeanfreauMetairie$13.4M
- Frederick DantagnanMetairie$421K
- William SmithNew Orleans$50.5M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.